Trial Results of New Pneumococcal Vaccine Compelling
Trial Results of New Pneumococcal Vaccine Compelling
Source: investorideas.com
Stay updated with breaking news from Readership Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Trial Results of New Pneumococcal Vaccine Compelling
FDA Approval of New Gout Drug Likely, Analyst Says
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants.